CoreWeave Financing Closes $8.5B DDTL

CoreWeave financing drew investment-grade ratings and major lenders, widening credit for its AI cloud platform and refocusing traders on AI infrastructure.

March 31, 2026·2 min read
View all news articles
Flat vector of a server rack merging into a reinforced lending vault symbolizing CoreWeave financing and AI cloud capacity expansion.

KEY TAKEAWAYS

  • Closed DDTL 4.0 with about $7.5B initial draw capacity, expandable to $8.5B.
  • Rated A3 by Moody's and A (low) by DBRS, the first investment-grade non-recourse HPC-backed facility.
  • Proceeds support AI cloud platform expansion and fulfillment of contracted services.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

CoreWeave, Inc. (Nasdaq: CRWV) closed a delayed-draw term loan on March 31, 2026, raising initial draw capacity of about $7.5 billion to support expansion of its AI cloud platform and contracted services. The CoreWeave financing drew investment-grade ratings from Moody's and DBRS.

Loan Structure and Syndicate

The delayed-draw term loan, branded DDTL 4.0, is secured by substantially all assets of CoreWeave Compute Acquisition Co. VIII, LLC. It initially supports roughly $7.5 billion of draws, with capacity rising to $8.5 billion as assets stabilize. The facility includes a floating tranche priced at SOFR plus 2.25% and a fixed tranche at about 5.9%, maturing in March 2032.

Lead arrangers included MUFG and Morgan Stanley as co-structuring agents and joint bookrunners, with Goldman Sachs and JPMorgan serving as coordinating lead arrangers. The transaction was anchored by Blackstone Credit & Insurance and was oversubscribed.

Ratings and Strategic Use

Moody's assigned an A3 rating and DBRS an A (low), marking the first investment-grade non-recourse facility backed by high-performance computing (HPC) and GPU infrastructure alongside an associated customer contract. The company said the financing "reflects further reduction in cost of capital and growing institutional confidence in CoreWeave’s model, execution, and AI adoption."

Proceeds will fund continued expansion of CoreWeave’s AI cloud platform and fulfill previously contracted cloud services with a leading AI enterprise. Aggregate equity and debt commitments tied to CoreWeave over the past 12 months now total about $28 billion. The company said the facility enables ongoing investment to meet customer demand for AI cloud services.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Berkshire Hathaway Buybacks Resume With Buffett's Backing

Berkshire Hathaway Buybacks Resume With Buffett's Backing

Berkshire Hathaway buybacks resumed in March 2026 with Warren Buffett's approval, signaling renewed buyback flow and capital-allocation trade for traders.

Whoop Funding Boosts IPO Prospect

Whoop Funding Boosts IPO Prospect

Whoop funding raised $575 million to accelerate global expansion and R&D and to ready the company toward IPO as investors watch membership and bookings.

Allbirds Sale to American Exchange Group

Allbirds Sale to American Exchange Group

Allbirds sale to American Exchange Group values the brand at $39 million and reframes equity value as shares jumped in after-hours trading.

Oracle Layoffs Hit Thousands as AI Spending Expands

Oracle Layoffs Hit Thousands as AI Spending Expands

Oracle layoffs signal cost cutting to redirect capital toward AI and data-center projects and shift investor focus to financing and operational risk.

Buffett Regrets Selling Apple, Would Buy If Cheap

Buffett Regrets Selling Apple, Would Buy If Cheap

Buffett Regrets Selling Apple. On March 31, 2026 he said he would buy only if Apple fell enough, keeping markets focused on valuation and cash.

Eli Lilly Centessa Acquisition Worth $7.8 Billion

Eli Lilly Centessa Acquisition Worth $7.8 Billion

Eli Lilly Centessa acquisition lists $38 per share upfront and up to $9 CVRs, expanding Lilly neuroscience pipeline and focusing traders on Q3 2026.